Intensive glucose control and risk of cancer in patients with type 2 diabetes

G Stefansdottir; S Zoungas; J Chalmers; A P Kengne; M J Knol; H G M Leufkens; A Patel; M Woodward; D E Grobbee; M L De Bruin

doi:10.1007/s00125-011-2104-x

Intensive glucose control and risk of cancer in patients with type 2 diabetes

G Stefansdottir, S Zoungas, J Chalmers, A P Kengne, M J Knol, H G M Leufkens, A Patel, M Woodward, D E Grobbee, M L De Bruin

33 Citations (Scopus)

Abstract

Aims/hypothesis: Type 2 diabetes has been associated with an increased risk of cancer. This study examines the effect of more vs less intensive glucose control on the risk of cancer in patients with type 2 diabetes. Methods: All 11,140 participants from the Action in Diabetes and Vascular Disease: Preterax and Diamicron-MR Controlled Evaluation (ADVANCE) trial (ClinicalTrials.gov NCT00145925) were studied. Cancer incidence and cancer mortality was compared in groups randomised to intensive or standard glucose control. Information on events during follow-up was obtained from serious adverse event reports and death certificates. HRs (95% CI) were calculated for all cancers, all solid cancers, cancer deaths and site-specific cancers. Results: After a median follow-up of 5 years, 363 and 337 cancer events were reported in the intensive and standard control groups, respectively (incidence 1.39/100 person-years [PY] and 1.28/100 PY; HR 1.08 [95% CI 0.93-1.26]). The incidences of all solid cancers and cancer deaths were 1.25/100 PY and 0.15/100 PY in the intensive group and 1.15/100 PY and 0.13/100 PY in the standard group (HR 1.09 [95% CI 0.93-1.27] for solid cancers, and 1.17 [0.75-1.84] for cancer death). Across all the major organ systems studied, no significant differences in the cancer incidences were observed in the intensive and standard control groups. Conclusions/interpretations: More intensive glucose control achieved with a regimen that included greater use of gliclazide, insulin, metformin and other agents, did not affect the risk of cancer events or death in patients with type 2 diabetes.

Original language	English
Journal	Diabetologia
Volume	54
Issue number	7
Pages (from-to)	1608-14
Number of pages	7
ISSN	0012-186X
DOIs	https://doi.org/10.1007/s00125-011-2104-x
Publication status	Published - Jul 2011
Externally published	Yes

Keywords

Aged
Blood Glucose
Diabetes Mellitus, Type 2
Female
Gliclazide
Humans
Hypoglycemic Agents
Insulin
Male
Metformin
Middle Aged
Neoplasms
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1007/s00125-011-2104-x

10.1007%2Fs00125-011-2104-x.pdfFinal published version, 182 KB

Cite this

@article{28bcc83f86f0493aafcebfc6e83acc76,

title = "Intensive glucose control and risk of cancer in patients with type 2 diabetes",

abstract = "Aims/hypothesis: Type 2 diabetes has been associated with an increased risk of cancer. This study examines the effect of more vs less intensive glucose control on the risk of cancer in patients with type 2 diabetes. Methods: All 11,140 participants from the Action in Diabetes and Vascular Disease: Preterax and Diamicron-MR Controlled Evaluation (ADVANCE) trial (ClinicalTrials.gov NCT00145925) were studied. Cancer incidence and cancer mortality was compared in groups randomised to intensive or standard glucose control. Information on events during follow-up was obtained from serious adverse event reports and death certificates. HRs (95% CI) were calculated for all cancers, all solid cancers, cancer deaths and site-specific cancers. Results: After a median follow-up of 5 years, 363 and 337 cancer events were reported in the intensive and standard control groups, respectively (incidence 1.39/100 person-years [PY] and 1.28/100 PY; HR 1.08 [95% CI 0.93-1.26]). The incidences of all solid cancers and cancer deaths were 1.25/100 PY and 0.15/100 PY in the intensive group and 1.15/100 PY and 0.13/100 PY in the standard group (HR 1.09 [95% CI 0.93-1.27] for solid cancers, and 1.17 [0.75-1.84] for cancer death). Across all the major organ systems studied, no significant differences in the cancer incidences were observed in the intensive and standard control groups. Conclusions/interpretations: More intensive glucose control achieved with a regimen that included greater use of gliclazide, insulin, metformin and other agents, did not affect the risk of cancer events or death in patients with type 2 diabetes.",

keywords = "Aged, Blood Glucose, Diabetes Mellitus, Type 2, Female, Gliclazide, Humans, Hypoglycemic Agents, Insulin, Male, Metformin, Middle Aged, Neoplasms, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't",

author = "G Stefansdottir and S Zoungas and J Chalmers and Kengne, {A P} and Knol, {M J} and Leufkens, {H G M} and A Patel and M Woodward and Grobbee, {D E} and {De Bruin}, {M L}",

year = "2011",

month = jul,

doi = "10.1007/s00125-011-2104-x",

language = "English",

volume = "54",

pages = "1608--14",

journal = "Diabetologia",

issn = "0012-186X",

publisher = "Springer",

number = "7",

}

TY - JOUR

T1 - Intensive glucose control and risk of cancer in patients with type 2 diabetes

AU - Stefansdottir, G

AU - Zoungas, S

AU - Chalmers, J

AU - Kengne, A P

AU - Knol, M J

AU - Leufkens, H G M

AU - Patel, A

AU - Woodward, M

AU - Grobbee, D E

AU - De Bruin, M L

PY - 2011/7

Y1 - 2011/7

N2 - Aims/hypothesis: Type 2 diabetes has been associated with an increased risk of cancer. This study examines the effect of more vs less intensive glucose control on the risk of cancer in patients with type 2 diabetes. Methods: All 11,140 participants from the Action in Diabetes and Vascular Disease: Preterax and Diamicron-MR Controlled Evaluation (ADVANCE) trial (ClinicalTrials.gov NCT00145925) were studied. Cancer incidence and cancer mortality was compared in groups randomised to intensive or standard glucose control. Information on events during follow-up was obtained from serious adverse event reports and death certificates. HRs (95% CI) were calculated for all cancers, all solid cancers, cancer deaths and site-specific cancers. Results: After a median follow-up of 5 years, 363 and 337 cancer events were reported in the intensive and standard control groups, respectively (incidence 1.39/100 person-years [PY] and 1.28/100 PY; HR 1.08 [95% CI 0.93-1.26]). The incidences of all solid cancers and cancer deaths were 1.25/100 PY and 0.15/100 PY in the intensive group and 1.15/100 PY and 0.13/100 PY in the standard group (HR 1.09 [95% CI 0.93-1.27] for solid cancers, and 1.17 [0.75-1.84] for cancer death). Across all the major organ systems studied, no significant differences in the cancer incidences were observed in the intensive and standard control groups. Conclusions/interpretations: More intensive glucose control achieved with a regimen that included greater use of gliclazide, insulin, metformin and other agents, did not affect the risk of cancer events or death in patients with type 2 diabetes.

AB - Aims/hypothesis: Type 2 diabetes has been associated with an increased risk of cancer. This study examines the effect of more vs less intensive glucose control on the risk of cancer in patients with type 2 diabetes. Methods: All 11,140 participants from the Action in Diabetes and Vascular Disease: Preterax and Diamicron-MR Controlled Evaluation (ADVANCE) trial (ClinicalTrials.gov NCT00145925) were studied. Cancer incidence and cancer mortality was compared in groups randomised to intensive or standard glucose control. Information on events during follow-up was obtained from serious adverse event reports and death certificates. HRs (95% CI) were calculated for all cancers, all solid cancers, cancer deaths and site-specific cancers. Results: After a median follow-up of 5 years, 363 and 337 cancer events were reported in the intensive and standard control groups, respectively (incidence 1.39/100 person-years [PY] and 1.28/100 PY; HR 1.08 [95% CI 0.93-1.26]). The incidences of all solid cancers and cancer deaths were 1.25/100 PY and 0.15/100 PY in the intensive group and 1.15/100 PY and 0.13/100 PY in the standard group (HR 1.09 [95% CI 0.93-1.27] for solid cancers, and 1.17 [0.75-1.84] for cancer death). Across all the major organ systems studied, no significant differences in the cancer incidences were observed in the intensive and standard control groups. Conclusions/interpretations: More intensive glucose control achieved with a regimen that included greater use of gliclazide, insulin, metformin and other agents, did not affect the risk of cancer events or death in patients with type 2 diabetes.

KW - Aged

KW - Blood Glucose

KW - Diabetes Mellitus, Type 2

KW - Female

KW - Gliclazide

KW - Humans

KW - Hypoglycemic Agents

KW - Insulin

KW - Male

KW - Metformin

KW - Middle Aged

KW - Neoplasms

KW - Journal Article

KW - Randomized Controlled Trial

KW - Research Support, Non-U.S. Gov't

U2 - 10.1007/s00125-011-2104-x

DO - 10.1007/s00125-011-2104-x

M3 - Journal article

C2 - 21509444

SN - 0012-186X

VL - 54

SP - 1608

EP - 1614

JO - Diabetologia

JF - Diabetologia

IS - 7

ER -

Intensive glucose control and risk of cancer in patients with type 2 diabetes

Abstract

Keywords

UN SDGs

Access to Document

Fingerprint

Cite this